0000000001229009

AUTHOR

Lutz G Prof Dr Guertler

showing 2 related works from this author

Pathogen safety of long-term treatments for bleeding disorders: (un)predictable risks and evolving threats.

2013

Substantial improvements in the safety of blood and plasma products for the management of bleeding disorders have been achieved in recent decades. This has led some clinicians to believe that the infectious threat is over and that inhibitor formation is the foremost complication of hemophilia therapy. On the contrary, elimination of all microbes from blood is difficult, potentially impossible, and there are always threats from emerging pathogens. The risk of infection transmission is also increasing due to greater exposure to products, increasing prophylaxis and high-dose regimens for immune tolerance, and longevity of hemophilia patients. Current products can be considered "reasonably safe…

medicine.medical_specialtyLong term treatmentContext (language use)Hemophilia AInfectionsEmerging infectionsSAFERHumans; Blood Coagulation Disorders; Hemophilia A; Blood Transfusion; InfectionmedicineHumansBlood TransfusionIntensive care medicinePathogenTransmission (medicine)business.industryRisk of infectionTransfusion ReactionHematologyBlood Coagulation Disordersmedicine.diseaseSettore MED/07 - Microbiologia e Microbiologia ClinicaThrombosisSurgeryHemostasisPlasma productsBlood safetyCardiology and Cardiovascular MedicinebusinessInfectionSeminars in thrombosis and hemostasis
researchProduct

Current concepts in the prevention of pathogen transmission via blood/plasma-derived products for bleeding disorders

2015

The pathogen safety of blood/plasma-derived products has historically been a subject of significant concern to the medical community, Measures such as donor selection and blood screening have contributed to increase the safety of these products, but pathogen transmission does still occur. Reasons for this include lack of sensitivity/specificity of current screening methods, lack of reliable screening tests for some pathogens (e.g. prions) and the fact that many potentially harmful infectious agents are not routinely screened for. Methods for the purification/inactivation of blood/plasma-derived products have been developed in order to further reduce the residual risk, but low concentrations…

0301 basic medicineriesgohumanosUltrafiltrationBacteremiaBlood DonorsHepacivirus030204 cardiovascular system & hematologyParasitemia/dk/atira/pure/subjectarea/asjc/2700/27200302 clinical medicineBlood plasmaScreening methodMedicinePathogenChromatographyultrafiltraciónfungemiaTransmission (medicine)Blood ScreeningbacteriemiaHematologyBlood Coagulation DisordersChromatography Ion ExchangeSettore MED/07 - Microbiologia e Microbiologia Clinicatransfusión de componentes sanguíneos/dk/atira/pure/subjectarea/asjc/2700/2730trastornos de la coagulación sanguíneaOncologyVIH-1RiskHepatitis B virusHaemophiliaBlood Component TransfusionHaemophiliaArticlepatógenos transmitidos por la sangre03 medical and health sciencesBlood-Borne PathogensHumansViremiacromatografíaBlood safety; Clotting; Haemophilia; Pathogen; TransfusionPathogenbusiness.industryDonor selectionTransfusionClottingdonantes de sangrevirus de la hepatitis Bmedicine.diseaseResidual risk030104 developmental biologyImmunologyHIV-1businessBlood safetyBlood Reviews
researchProduct